We are developing potentially life-changing one-time gene therapies for neurodegenerative diseases. Our current platform is just the beginning of a continuum of investment in next generation gene therapy technologies and capabilities.
We welcome the opportunity to develop long-term and successful alliances with other groups through tailored partnerships, high-value research initiatives and global leadership projects. Please contact us.
Lysogene has a highly networked R&D structure leveraging modularity and learning from others. We collaborate with some of the world’s best research laboratories, scientists and clinicians.
Lysogene collaborates with University of Massachusetts Medical School (UMMS) for pre-clinical efficacy studies of innovative AAV-based gene therapy approaches in the GM1 gangliosidosis mouse model.
UMMS, one of five campuses of the University system, is comprised of the School of Medicine, the Graduate School of Biomedical Sciences, the Graduate School of Nursing, a thriving research enterprise and an innovative public service initiative, Commonwealth Medicine. Its mission is to advance the health of the people of the Commonwealth through pioneering education, research, public service and health care delivery with its clinical partner, UMass Memorial Health Care. In doing so, it has built a reputation as a world-class research institution and as a leader in primary care education. The Medical School attracts more than $240 million annually in research funding, placing it among the top 50 medical schools in the nation. In 2006, UMMS’s Craig C. Mello, PhD, Howard Hughes Medical Institute Investigator and the Blais University Chair in Molecular Medicine, was awarded the Nobel Prize in Physiology or Medicine, along with colleague Andrew Z. Fire, PhD, of Stanford University, for their discoveries related to RNA interference (RNAi). The 2013 opening of the Albert Sherman Center ushered in a new era of biomedical research and education on campus. Designed to maximize collaboration across fields, the Sherman Center is home to scientists pursuing novel research in emerging scientific fields with the goal of translating new discoveries into innovative therapies for human diseases.
Lysogene collaborates with Auburn University for pre-clinical efficacy studies of innovative AAV-based gene therapy approaches in the naturaly occuring GM1 gangliosidosis feline model.
AU has provided instruction, research and outreach to benefit the state of Alabama and the nation for more than 155 years and is among a distinctive group of universities designated as Land, Sea and Space Grant institutions. Auburn makes a nearly $5 billion economic contribution to the state each year, has more than 250,000 graduates and provides 140 degree programs to more than 25,000 graduate and undergraduate students. For more news about Auburn University, go to www.auburn.edu. The College of Veterinary Medicine, the oldest veterinary medical program in the South, has a mission to prepare individuals for careers of excellence in veterinary medicine, including private and public practice, industrial medicine, academics, and research. The College is devoted to three strategic goals: (1) enhance student success; (2) promote discovery; and (3) practice the highest standards of veterinary medicine. For more, go to www.vetmed.auburn.edu. The Scott-Ritchey Research Center’s mission is to improve the health of companion animals and translate those findings to the clinical and scientific communities to facilitate their application in humans.